The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design

The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design

Aims Cachexia, the wasting disorder associated with a wide range of serious illnesses including cancer, is a major cause of morbidity and mortality. There is currently no widely approved therapeutic agent for treating or preventing cancer-associated cachexia. Colorectal cancer and nonsmall cell l...

Full description

Bibliographic Details
Main Authors: Stewart Coats, Andrew J., Srinivasan, Venkatesan, Surendran, Jayaraman, Chiramana, Haritha, Vangipuram, Shankar R. K. G., Bhatt, Nirajkumar N., Jain, Minish, Shah, Sandip, Ali, Irfhan A. B. H., Fuang, Ho G., Mat Hassan, Mohd. Zailani, Beadle, John, Tilson, Julia, Kirwan, Bridget-Anne, Anker, Stefan D.
Format: Article
Language:English
Published: Springer 2011
Subjects:
R Medicine (General)
Online Access:http://irep.iium.edu.my/18416/
http://irep.iium.edu.my/18416/1/13539_2011_Article_46.pdf

Similar Items

Similar Items